Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RLAY with free AI briefings, catalyst countdowns, and dilution alerts.

RLAY · Relay Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$848.6M Cash on Hand
43.1mo Cash Runway
Follow RLAY by email Get an email when RLAY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RLAY, unsubscribe in one click. Privacy

📣 What RLAY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Capivasertib PIK3CA Mutation Phase 3 · NCT06982521 Recruiting
Zovegalisib (RLY-2608) PIK3CA Mutation Phase 3 · NCT06982521 Recruiting
NRAS Inhibitor RLY-8161 Advanced NRAS-Mutant Melanoma Phase 1/2 · NCT07584226 Recruiting
Atirmociclib PIK3CA Mutation Phase 1 · NCT05216432 Recruiting
Pan-mutant-selective PI3K-alpha Inhibitor… PIK3CA Mutation Phase 1 · NCT05759949 Completed

Also used in these trials (approved or third-party drugs, not RLAY's own candidates): Fulvestrant, Abemaciclib, Palbociclib, Ribociclib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RLAY holds $848.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $59M/quarter from operations, an estimated runway of 43.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 24 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RLAY files for a raise →

👥 Who Owns RLAY

Insiders 10.9% Institutions (363 holders) 89.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
SVF Pauling (Cayman) Ltd
10% owner
Insider 21,904,963 9.91% 2026-08-25
FMR LLC Institution (13G, 5%+) 21,270,751 9.63% 2026-07-31
Perceptive Advisors LLC Institution (13G, 5%+) 14,106,187 6.38% 2026-06-30
CASDIN CAPITAL, LLC Institution (13G, 5%+) 13,003,574 5.89% 2025-12-31
Commodore Capital LP Institution (13G, 5%+) 12,000,000 5.43% 2026-06-30
Sanjiv Patel
President and CEO, Director · +1.45M options
Insider 1,358,204 0.61% 2026-10-07
Donald A Bergstrom
President, R&D · +575,000 options
Insider 396,878 0.18% 2026-10-28
Peter Rahmer
Chief Corporate Development Officer · +475,000 options
Insider 222,904 0.10% 2026-10-28
Thomas Catinazzo
Chief Financial Officer · +623,440 options
Insider 103,665 0.05% 2026-10-28

Share count 220,959,470 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RLAY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RLAY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.